TABLE 3.
Determinants for the first switch to a second biological for IBD patients
|
No. cases N = 136 |
No. controls N = 459 |
OR (univariate) 95% CI |
OR (multivariate) 95% CI |
|
|---|---|---|---|---|
| Median (IQR) age at index date | 38.6 (31.8) | 32.7 (31.9) | 1.01 (0.99–1.02) | — |
| Gender | ||||
| Males | 61 (44.9%) | 204 (44.4%) | Ref | |
| Females | 75 (55.1%) | 255 (55.6%) | 0.97 (0.66–1.43) | — |
| TNFα dose escalation | ||||
| No | 91 (66.9%) | 424 (92.4%) | Ref | |
| Yes | 45 (33.1%) | 35 (7.6%) | 10.83 (5.51–21.26)* | 8.22 (3.76–17.93) |
| Initiation/dose escalation immunomodulator | ||||
| No | 95 (69.9%) | 415 (90.4%) | Ref | |
| Yes | 41 (30.1%) | 44 (9.6%) | 4.45 (2.65–7.89)* | 2.13 (1.04–4.34) |
| High‐dose corticosteroid | ||||
| No | 109 (80.2%) | 440 (95.9%) | Ref | |
| Yes | 27 (19.8%) | 19 (4.1%) | 8.12 (3.74–17.62)* | 6.91 (2.81–17.01) |
| Serum concentration measurement | ||||
| No | 86 (63.2%) | 405 (88.2%) | Ref | |
| Yes | 50 (36.8%) | 54 (11.8%) | 6.55 (3.65–11.77) | 5.44 (2.74–10.79) |
*
p‐value <.1.